ArticleThe Journal of infectious diseases2019
Dynamic Perspectives on the Search for a Universal Influenza Vaccine.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Advances in the Development of a Universal Influenza Vaccine.Antibodies (Basel, Switzerland) · 2026Review
- Histone Demethylase JMJD2D Suppresses Influenza A Virus Infection by Promoting RIG-I Expression.Biomolecules · 2026Article
- Childhood immune imprinting shapes cohort and period influenza mortality.Science advances · 2026Article
- Monitoring Influenza A Virus Entry Using Quantitative Fluorescence Microscopy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Characterization of serum metabolome and respiratory microbiota in children with influenza A virus infection.Frontiers in cellular and infection microbiology · 2024Article
- An agent-based nested model integrating within-host and between-host mechanisms to predict an epidemic.PloS one · 2023Article
- Effects of epistasis and recombination between vaccine-escape and virulence alleles on the dynamics of pathogen adaptation.Nature ecology & evolution · 2022Article
- Targeted vaccination and the speed of SARS-CoV-2 adaptation.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Human Influenza Epidemiology.Cold Spring Harbor perspectives in medicine · 2021Review
- Vaccine nationalism and the dynamics and control of SARS-CoV-2.Science (New York, N.Y.) · 2021Article
- Epidemic situation of the complex seasonality of imported influenza A and B virus transmission in Guangxi ports of ChinaTurkish journal of medical sciences · 2021Article
- Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.Science (New York, N.Y.) · 2021Article
- Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.medRxiv : the preprint server for health sciences · 2021Article
- Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine.PLoS pathogens · 2020Review
- Implications of localized charge for human influenza A H1N1 hemagglutinin evolution: Insights from deep mutational scans.PLoS computational biology · 2020Article
- Economic and Behavioral Influencers of Vaccination and Antimicrobial Use.Frontiers in public health · 2020Review
- Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine.The Journal of infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A universal influenza vaccine (UIV) could considerably alleviate the public health burden of both seasonal and pandemic influenza. Although significant progress has been achieved in clarifying basic immunology and virology relating to UIV, several important questions relating to the dynamics of infection, immunity, and pathogen evolution remain unsolved. In this study, we review these gaps, which span integrative levels, from cellular to global and timescales from molecular events to decades. We argue that they can be best addressed by a tight integration of empirical (laboratory, epidemiological) research and theory and suggest fruitful areas for this synthesis. In particular, quantifying natural and vaccinal limitations on viral transmission are central to this effort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.